Summary
The RE-LY trial compared two doses of dabigatran (110 mg BID and 150 mg BID) with open label warfarin (target INR 2 to 3) in 18,113 patients with nonvalvular atrial fibrillation. This post hoc subanalyses from RE-LY, compares the efficacy and safety of dabigatran with warfarin in patients dependent upon use of concomitant antiplatelet therapy.
- Arrhythmias
- Cerebrovascular Disease
- Cerebrovascular Disease Clinical Trials
- © 2011 MD Conference Express
Tools
Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin
Permalink:
Table of contents
Cited By...
- No citing articles found.